AAPM has contracted with NCRP to provide each AAPM Member in good standing access and download privileges of electronically available NCRP reports, commentaries and statements. This report was prepared by the National Council on Radiation Protection and Measurements (NCRP). The Council strives to provide accurate, complete and useful information in its reports. However, neither the NCRP, the members of NCRP, other persons contributing to or assisting in the preparation of this report, nor any person acting on the behalf of any of these parties (a) makes any warranty or representation, express or implied, with respect to the accuracy, completeness or usefulness of the information contained in this report, or that the use of any information, method or process disclosed in this report may not infringe on privately owned rights; or (b) assumes any liability with respect to the use of, or for damages resulting from the use of, any information, method or process disclosed in this report.
 |
Report No. 070 - Nuclear Medicine - Factors Influencing the Choice and Use of Radionuclides in Diagnosis and Therapy (1982)  Price: $50 PDF (AAPM Members FREE) Category: Reports Report No. 70 offers broad guidance to those using radionuclides for medical purposes. This Report addresses the many factors which influence the choice of the proper radio pharmaceutical drug product for the diagnosis or treatment of a specific disease or condition. The Report examines decision-making considerations in the choice of radiopharmaceutical drug products and factors relevant to the choice of instruments utilized in nuclear medicine procedures. Important parts of the Report treat radiation dose and the evaluation of radionuclide procedures in their clinical utility. The Report also includes guidelines for performing nuclear medicine procedures. One appendix sets out the guidelines for clinical evaluation of radiopharmaceutical drugs developed by the Food and Drug Administration's Radiopharmaceutical Advisory Committee. Another appendix contains estimates of absorbed dose known for radiopharmaceutical drug products. Scientific Committee: A. Bertrand Brill, Chairman Ten expert members and consultants. |
DISCLAIMER